Bio-Techne (NASDAQ:TECH) Shares Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on April 29th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Dayforce (NYSE:DAY) on 4/28/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/24/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/16/2025.
• Sold $1,001 – $15,000 in shares of A. O. Smith (NYSE:AOS) on 4/10/2025.
• Sold $1,001 – $15,000 in shares of Toro (NYSE:TTC) on 4/10/2025.
• Purchased $1,001 – $15,000 in shares of Bio-Techne (NASDAQ:TECH) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of IDEXX Laboratories (NASDAQ:IDXX) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of Markel Group (NYSE:MKL) on 4/9/2025.
• Purchased $1,001 – $15,000 in shares of BJ’s Wholesale Club (NYSE:BJ) on 4/9/2025.

Bio-Techne Stock Down 1.4 %

Bio-Techne stock opened at $49.80 on Tuesday. The firm’s 50 day moving average price is $55.64 and its two-hundred day moving average price is $66.78. The firm has a market cap of $7.87 billion, a PE ratio of 50.30, a P/E/G ratio of 2.88 and a beta of 1.46. Bio-Techne Co. has a twelve month low of $46.01 and a twelve month high of $85.57. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. On average, research analysts predict that Bio-Techne Co. will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, February 28th. Investors of record on Monday, February 17th were issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne’s dividend payout ratio is currently 32.32%.

Hedge Funds Weigh In On Bio-Techne

A number of institutional investors and hedge funds have recently bought and sold shares of TECH. Allianz Asset Management GmbH boosted its holdings in Bio-Techne by 200.8% in the 1st quarter. Allianz Asset Management GmbH now owns 41,697 shares of the biotechnology company’s stock valued at $2,445,000 after purchasing an additional 27,833 shares during the period. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Bio-Techne by 3.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 12,160 shares of the biotechnology company’s stock valued at $713,000 after buying an additional 429 shares during the period. Verdence Capital Advisors LLC grew its position in Bio-Techne by 11.1% during the first quarter. Verdence Capital Advisors LLC now owns 13,295 shares of the biotechnology company’s stock worth $779,000 after buying an additional 1,328 shares in the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Bio-Techne by 3.4% during the first quarter. Kornitzer Capital Management Inc. KS now owns 188,035 shares of the biotechnology company’s stock valued at $11,024,000 after acquiring an additional 6,101 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Bio-Techne by 18.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,025,409 shares of the biotechnology company’s stock worth $177,380,000 after acquiring an additional 472,847 shares during the period. Institutional investors own 98.95% of the company’s stock.

Insider Transactions at Bio-Techne

In related news, Director Amy E. Herr sold 1,860 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the transaction, the director now owns 1,976 shares of the company’s stock, valued at $130,336.96. This represents a 48.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TECH has been the topic of several recent research reports. Robert W. Baird lowered shares of Bio-Techne from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $88.00 to $68.00 in a research report on Wednesday, February 19th. Scotiabank lifted their price objective on shares of Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 6th. Baird R W downgraded shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Evercore ISI initiated coverage on Bio-Techne in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $75.00 price target for the company. Finally, KeyCorp reissued a “sector weight” rating on shares of Bio-Techne in a research report on Wednesday, April 9th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Bio-Techne currently has an average rating of “Hold” and a consensus target price of $81.14.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.